Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting

 

Oslo, 03 November 2020: In connection with the Extraordinary General Meeting of
Ultimovacs ASA to be held on 11 November 2020, Jónas Einarsson, Chairman of the
Board of Directors, has so far received proxy based voting rights without voting
instructions for 9,906,810 shares, representing 30.98% of the total voting
rights in the company. 

With the addition of the 1.498.913 shares controlled by Radforsk, Jónas
Einarsson thus represents a total of 11,405,723 shares. This corresponds to
35.67% of the company's total number of shares and votes in connection with the
company's Extraordinary General Meeting.
 
The proxies are only valid for the Extraordinary General Meeting on 11 November
2020. 

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.


For further information, please see www.ultimovacs.com or contact:

Jónas Einarsson, Chairman of the Board of Directors of Ultimovacs ASA
Email: je@radforsk.no
Phone: +47 480 96 355

Carlos de Sousa, CEO 
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507 
	
Hans Vassgård Eid, CFO 
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632